返回 
加入收藏
小金丸联合多西他赛、表柔比星、环磷酰胺治疗Ⅲ期乳腺癌的疗效及对患者免疫功能的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | 小金丸联合多西他赛、表柔比星、环磷酰胺治疗Ⅲ期乳腺癌的疗效及对患者免疫功能的影响 |
| TITLE： | |
| 摘要： | 目的：探讨小金丸联合多西他赛、表柔比星、环磷酰胺治疗Ⅲ期乳腺癌的疗效、安全性及对患者免疫功能的影响。方法：102例Ⅲ期乳腺癌女性患者随机分为对照组（51例）和观察组（51例）。所有患者化疗期间均予以水化、碱化及止吐等对症治疗，分别于化疗前12、6 h口服地塞米松片0.75 mg等常规治疗；在此基础上，对照组患者给予注射用多西他赛75 mg/m2，d1，静脉滴注+注射用盐酸表柔比星60 mg/m2，d1，静脉注射+注射用环磷酰胺600 mg/m2，d1，静脉注射；观察组患者在对照组治疗的基础上给予小金丸6 g，口服，每日2次，初次化疗开始至末次化疗结束均需用药。两组均以21 d为1个周期，所有患者均治疗4个周期后观察其近期临床疗效，化疗前后的免疫球蛋白、T细胞亚群（CD4+/CD3+、CD8+/CD3+、CD4+/CD8+）及不良反应发生情况。结果：两组患者近期总有效率、不良反应发生率比较，差异均无统计学意义（P＞0.05）。化疗前，两组患者免疫球蛋白、T细胞亚群比较，差异均无统计学意义（P＞0.05）。化疗后，两组患者免疫球蛋白水平均显著低于同组治疗前，差异均有统计学意义（P＜0.05），但两组间比较差异均无统计学意义（P＞0.05）；对照组患者CD4+/CD3+、CD8+/CD3+、CD4+/CD8+及观察组患者CD8+/CD3+均显著低于同组治疗前，且观察组CD4+/CD3+、CD4+/CD8+高于对照组，差异均有统计学意义（P＜0.05），但两组CD8+/CD3+比较差异无统计学意义（P＞0.05）。结论：在常规治疗的基础上，小金丸联合多西他赛、表柔比星、环磷酰胺治疗Ⅲ期乳腺癌疗效显著，可提高患者细胞免疫功能，且安全性较好。 |
| ABSTRACT： | OBJECTIVE： To investigate the efficacy and safety of Xiaojin pill combined with docetaxel， epirubicin and cyclophosphamide in the treatment of breast cancer in stage Ⅲ and its effect on immune functions. METHODS： 102 patients with breast cancer in stage Ⅲ were randomly divided into control group （51 cases） and observation group（51 cases）. All patients were given symptomatic treatments as hydration，alkalization and antiemetic treatments in the duration of chemotherapy，and were given conventional treatments as 0.75 mg Dexamethasome oral tablets in 12 and 6 hours before the chemotherapy lespectively. Control group was given 75 mg/m2 Docetaxel injection， d1， intravenous infusion+60 mg/m2 Epirubicin hyclrochloride for injection， d1， intravenous infusion+600 mg/m2 Cyclophosphamide for injection， d1， intravenous infusion； observation group was additionally given 6 g Xiaojin pill， orally， twice a day. 21 d was regarded as a treatment course. Short-term clinical efficacy， immunoglobulin， T lymphocyte subsets （CD4+/CD3+， CD8+/CD3+， CD4+/CD8+） and the incidence of adverse reactions before and after chemotherapy in 2 groups after 2 courses were observed. RESULTS： There were no significant differences in the short-term effective rate and incidence of adverse reactions between 2 groups （P＞0.05）. Before chemotherapy， there were no significant differences in the immunoglobulin and T lymphocyte subsets between 2 groups （P＞0.05）. After chemotherapy， immunoglobulin levels in 2 groups were significantly lower than before， the differences were statistically significant （P＜0.05）； but there were no significant differences between 2 groups （P＞0.05）； CD4+/CD3+， CD8+/CD3+， CD4+/CD8+ in control group and CD8+/CD3+ in observation group were significantly lower than before， and CD4+/CD3+ and CD4+/CD8+ in observation group were higher than control group， the differences were statistically significant （P＜0.05）， but there was no significant difference in the CD8+/CD3+ between 2 groups （P＞0.05）. CONCLUSIONS： Based on the conventional treatment， Xiaojin pill combined with docetaxel， epirubicin and cyclophosphamide shows significant efficacy in the treatment of breast cancer in stage Ⅲ， and can improve immune functions， with good safety. |
| 期刊： | 2016年第27卷第15期 |
| 作者： | 张超，冯秀芳，王秀云，刘广寅 |
| AUTHORS： | ZHANG Chao，FENG Xiufang，WANG Xiuyun，LIU Guangyin |
| 关键字： | 乳腺癌；小金丸；多西他赛；表柔比星；环磷酰胺；疗效；免疫功能；安全性 |
| KEYWORDS： | Breast cancer； Xiaojin pill； Docetaxel； Epirubicin； Cyclophosphamide； Efficacy； Immune function； Safety |
| 阅读数： | 457 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
